Is NeuroSense Therapeutics Stock a Good Investment?
NeuroSense Therapeutics Investment Advice | NRSNW |
- Examine NeuroSense Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research NeuroSense Therapeutics' leadership team and their track record. Good management can help NeuroSense Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact NeuroSense Therapeutics' business and its evolving consumer preferences.
- Compare NeuroSense Therapeutics' performance and market position to its competitors. Analyze how NeuroSense Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if NeuroSense Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about NeuroSense Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in NeuroSense Therapeutics Ltd stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if NeuroSense Therapeutics Ltd is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Good | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine NeuroSense Therapeutics Stock
Researching NeuroSense Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 0.94. NeuroSense Therapeutics had not issued any dividends in recent years.
To determine if NeuroSense Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding NeuroSense Therapeutics' research are outlined below:
| NeuroSense Therapeutics is way too risky over 90 days horizon | |
| NeuroSense Therapeutics has some characteristics of a very speculative penny stock | |
| NeuroSense Therapeutics appears to be risky and price may revert if volatility continues | |
| NeuroSense Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (11.28 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NeuroSense Therapeutics Ltd has accumulated about 994 K in cash with (8.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.13. | |
| NeuroSense Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: NeuroSense Therapeutics Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC Form 6 K - Marketscreener.com |
NeuroSense Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.18) | (3.34) | |
| Return On Capital Employed | 42.58 | 44.70 | |
| Return On Assets | (3.18) | (3.34) | |
| Return On Equity | 5.39 | 5.66 |
Determining NeuroSense Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if NeuroSense Therapeutics is a good buy. For example, gross profit margin measures NeuroSense Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of NeuroSense Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in NeuroSense Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of NeuroSense Therapeutics Ltd. Check NeuroSense Therapeutics' Beneish M Score to see the likelihood of NeuroSense Therapeutics' management manipulating its earnings.
Evaluate NeuroSense Therapeutics' management efficiency
The company has return on total asset (ROA) of (1.5079) % which means that it has lost $1.5079 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (4.9484) %, meaning that it generated substantial loss on money invested by shareholders. NeuroSense Therapeutics' management efficiency ratios could be used to measure how well NeuroSense Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, NeuroSense Therapeutics' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 5.66 in 2024, whereas Return On Tangible Assets are likely to drop (3.34) in 2024. At this time, NeuroSense Therapeutics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 23.4 K in 2024, whereas Other Current Assets are likely to drop slightly above 97 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.14) | (0.13) | |
| Tangible Book Value Per Share | (0.14) | (0.13) | |
| Enterprise Value Over EBITDA | (0.77) | (0.81) | |
| Price Book Value Ratio | (5.71) | (5.43) | |
| Enterprise Value Multiple | (0.77) | (0.81) | |
| Price Fair Value | (5.71) | (5.43) | |
| Enterprise Value | 12.3 M | 12.9 M |
Leadership effectiveness at NeuroSense Therapeutics Ltd is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 1.565 |
Basic technical analysis of NeuroSense Stock
As of the 15th of December 2024, NeuroSense Therapeutics secures the Mean Deviation of 18.17, risk adjusted performance of 0.1157, and Downside Deviation of 30.44. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NeuroSense Therapeutics, as well as the relationship between them. Please verify NeuroSense Therapeutics jensen alpha and semi variance to decide if NeuroSense Therapeutics Ltd is priced some-what accurately, providing market reflects its recent price of 0.25 per share. As NeuroSense Therapeutics appears to be a penny stock we also strongly suggest to check its total risk alpha numbers.Understand NeuroSense Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing NeuroSense Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1157 | |||
| Market Risk Adjusted Performance | (0.71) | |||
| Mean Deviation | 18.17 | |||
| Semi Deviation | 19.74 | |||
| Downside Deviation | 30.44 | |||
| Coefficient Of Variation | 684.41 | |||
| Standard Deviation | 27.75 | |||
| Variance | 770.32 | |||
| Information Ratio | 0.1425 | |||
| Jensen Alpha | 4.55 | |||
| Total Risk Alpha | 0.5961 | |||
| Sortino Ratio | 0.1299 | |||
| Treynor Ratio | (0.72) | |||
| Maximum Drawdown | 158.33 | |||
| Value At Risk | (42.31) | |||
| Potential Upside | 58.82 | |||
| Downside Variance | 926.88 | |||
| Semi Variance | 389.77 | |||
| Expected Short fall | (28.04) | |||
| Skewness | 0.7412 | |||
| Kurtosis | 2.28 |
| Risk Adjusted Performance | 0.1157 | |||
| Market Risk Adjusted Performance | (0.71) | |||
| Mean Deviation | 18.17 | |||
| Semi Deviation | 19.74 | |||
| Downside Deviation | 30.44 | |||
| Coefficient Of Variation | 684.41 | |||
| Standard Deviation | 27.75 | |||
| Variance | 770.32 | |||
| Information Ratio | 0.1425 | |||
| Jensen Alpha | 4.55 | |||
| Total Risk Alpha | 0.5961 | |||
| Sortino Ratio | 0.1299 | |||
| Treynor Ratio | (0.72) | |||
| Maximum Drawdown | 158.33 | |||
| Value At Risk | (42.31) | |||
| Potential Upside | 58.82 | |||
| Downside Variance | 926.88 | |||
| Semi Variance | 389.77 | |||
| Expected Short fall | (28.04) | |||
| Skewness | 0.7412 | |||
| Kurtosis | 2.28 |
Consider NeuroSense Therapeutics' intraday indicators
NeuroSense Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of NeuroSense Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.66 | |||
| Day Median Price | 0.25 | |||
| Day Typical Price | 0.25 | |||
| Price Action Indicator | (0.07) | |||
| Period Momentum Indicator | (0.13) | |||
| Relative Strength Index | 42.9 |
NeuroSense Stock media impact
Far too much social signal, news, headlines, and media speculation about NeuroSense Therapeutics that are available to investors today. That information is available publicly through NeuroSense media outlets and privately through word of mouth or via NeuroSense internal channels. However, regardless of the origin, that massive amount of NeuroSense data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of NeuroSense Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of NeuroSense Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to NeuroSense Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive NeuroSense Therapeutics alpha.
NeuroSense Therapeutics Corporate Management
| Yael Barak | VP Compliance | Profile | |
| Ferenc Tracik | Chief Officer | Profile | |
| Or Eisenberg | Chief Officer | Profile | |
| Alon BenNoon | CEO CoFounder | Profile | |
| Hagit Binder | Chief Officer | Profile | |
| Oron DVM | Chief Officer | Profile | |
| Ferenc MD | Chief Officer | Profile |
Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.